Glycogen storage disease Ib (SLC37A4) OMIM 232220

In Glycogen storage disease Ib (SLC37A4, OMIM 232220), the master switch sits on the ↑ UP branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5132, γ 1.4327, spinodal 0.6601). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for Glycogen storage disease Ib is an R19 double-well emerged from the real proximal-promoter DNA of SLC37A4. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis: ↑ UP [F]
healthy branch: ON
lesion: LOF_null
γ (stiffness): 1.4327
barrier: 0.5132
spinodal: 0.6601
s_on / s_off: 1.1970 / -1.1970
fragility: 0.39
corrective polarity: clear
forced direction: raise s toward ON branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.5132 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: decreasegeometric rank 0.39

Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)

Applies to. allele-agnostic (downstream/environmental tilt)

favoured when the switch is fragile -- a small drive shift recrosses the fold

Falsifier. If clearing/opposing the accumulating 1,5-anhydroglucitol-6-phosphate accumulation that impairs neutrophils in the SLC37A4 glucose-6-phosphate-transporter defect does NOT relieve the disease branch in a SLC37A4 model, the h-restore(clear) lever is refuted for this axis.

gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00

Mechanism. N/A

Applies to. none (honest exclusion)

EXCLUDED: null allele -- no product to stiffen

Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual SLC37A4 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: SGLT2 inhibition (empagliflozin) reducing the 1,5-anhydroglucitol-6-phosphate accumulation that impairs neutrophils in the SLC37A4 defect. The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.

Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)	dir.	status	phase	map
SGLT2 inhibition (empagliflozin) reducing the 1,5-anhydroglucitol-6-phosphate accumulation that impairs neutrophils in the SLC37A4 defect Veiga-da-Cunha 2019 Proc Natl Acad Sci U S A 116:1241 (failure to eliminate a phosphorylated glucose analog); Gerin 1997 FEBS Lett 419:235 (sequence of a putative glucose 6-phosphate translocase,)	decrease	established / off-label	0	✓ in use

⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
element	grade	basis
R19 switch & cusp geometry (this page)	[V] verified	emerged from measured promoter γ of `SLC37A4`; deterministic, 2×sha256 identical
corrective direction	[F] forced	forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads	[O] open	direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).